COMPLEMENT INHIBITORY AGENTS AS THERAPEUTICS IN POSTTRAUMATIC AND DEGENERATIVE ARTHRITIS
First Claim
1. A method of treating a subject at risk of developing or currently having osteoarthritis, comprisingadministering to the subject a complement inhibitor compound in a therapeutically effective amount
7 Assignments
0 Petitions
Accused Products
Abstract
The present disclosure is directed to methods and compositions for treating osteoarthritis and preventing osteoarthritis, by administering a compound that modulates one or more components in the complement system. In one embodiment, a compound that inhibits a component in the complement system is administered to prevent, delay the progression of, or treat osteoarthritis. In other embodiments, compounds with specific inhibition of a component in a particular pathway in the complement system, such as the alternative, mannose binding lectin, and/or classical pathway, are administered to a subject having osteoarthritis or at risk of developing osteoarthritis.
-
Citations
20 Claims
-
1. A method of treating a subject at risk of developing or currently having osteoarthritis, comprising
administering to the subject a complement inhibitor compound in a therapeutically effective amount
-
19. A method of preventing, delaying, or reducing the probability of development of osteoarthritis in a human subject, comprising:
administering to the subject a complement inhibitor compound in a therapeutically effective amount.
-
20. A method of slowing or inhibiting the progression of osteoarthritis in a subject at risk of developing osteoarthritis or currently having osteoarthritis, comprising:
administering to the subject a complement inhibitor compound or a functional equivalent thereof in a prophylactically or therapeutically effective amount.
Specification